 Effects sulfonylureas adipocyte skeletal muscle insulin action patients non-insulin-dependent diabetes mellitus effect glibenclamide treatment insulin action isolated fat cells obese patients non-insulin-dependent diabetes NIDDM Insulin receptor binding effect insulin glucose transport lipogenesis months glibenclamide therapy end treatment period mean daytime plasma glucose concentrations versus mmol/L whereas daytime plasma insulin level versus mU/L Adipocyte insulin receptor binding basal glucose transport metabolism drug treatment contrast insulin-stimulated glucose transport lipogenesis findings comparable study obese subjects NIDDM biopsies lateral vastus muscle measurement insulin receptor function glycogen synthase activity months gliclazide treatment study insulin receptors wheatgerm agglutinin unchanged insulin binding receptor kinase activity gliclazide impact maximal glycogen synthase activity physiologic hyperinsulinemic conditions therapy increased sensitivity glycogen synthase allosteric activation conclusion sulfonylurea treatment NIDDM insulin-stimulated peripheral glucose utilization part potentiation insulin action adipose tissue glucose transport lipogenesis skeletal muscle glycogen synthase